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Abstract  
Pancreatic cancer is one of the most lethal cancers with high metastatic potential and strong 
chemoresistance. The capability of a tumor to grow and propagate is dependent on a small subset 
of cells within a tumor, termed cancer stem cells. Cancer stem cells exhibit great tumorigenicity 
and are closely correlated with drug resistance and tumor recurrence. The aim of our study was 
to illustrate electrochemotherapy as an effective treatment for pancreatic cancer along with the 
expression change in stemness genes (Nanog, Sox2 and Oct3/4) in pancreatic cancer cells post 
electrochemotherapy with bleomycin, cisplatin and oxaliplatin. Our results showed the enhanced 
expression of Nanog and decreased expression level of Oct3/4 after electrochemotherpy. We 
thus propose that these stemness marker may have important roles in the initiation and/or 
recurrence of pancreatic cancer, and consequently may serve as important molecular diagnostics 
and/or therapeutic targets for the development of novel treatment strategies in pancreatic cancer 
patients. In conclusion, targeting these stemness factors could potentially improve 
electrochemotherapy as a treatment and preventing recurrence. 
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1. Introduction 
Pancreatic cancer continues to be one of the deadliest cancers with a high metastatic potential 
and strong chemoresistance [1]. The incidence of pancreatic cancer increases each year with no 
significant decrease in mortality [2]. Almost 90% of pancreatic malignancies are pancreatic 
ductal adenocarcinomas (PDACs) [3]. PDAC is associated with a poor prognosis and has 
become the fourth most common cause of cancer-related mortality. The 5-year survival of 
patients is dismal at 6% or less [3].  
Currently for early disease stage surgery followed by adjuvant therapy is the treatment option for 
most patients. However, majority of patients present with locally advanced disease or metastatic 
disease which makes resection difficult [4]. Conventional therapeutic strategies have resulted in 
decreased perioperative morbidity and mortality after pancreatic resection, but this has not 
improved the median overall survival of patients with localized operable pancreatic cancer. Thus, 
there is a need for alternative therapeutic strategy is needed to improve the therapeutic situation 
of patients with PDAC [4]. 
Electrochemotherapy (ECT) is a cancer treatment, a non-thermal cell permeabilisation 
technology that renders the treated cell membranes permeable to otherwise impermenant or 
poorly permeant chemotherapeutics [5]. The use of ECT for tumor treatments leads to a local 
potentiation of chemotherapy by reducing the doses of the drugs, minimizing the side effects, 
and increasing the efficacy of chemotherapy [6]. ECT is regularly used for cutaneous and 
subcutaneous metastases and is an effective treatment and with the advancement of new medical 
devices this is now a treatment option for deep seated tumors including pancreatic cancer [7]. 
One concerning feature of pancreatic cancer is the high resistance to treatments. Even for 
patients with resectable disease, most of them will relapse [8]. Therefore, it is crucial to 
understand mechanisms that cause treatment resistance and is crucial to help develop new 
effective treatments for this deadly disease. PDAC has a high level of Cancer Stem Cells (CSCs) 
[9]. CSCs are highly resistant to conventional chemotherapy and radiotherapy and are considered 
a cause of tumor relapse after eradication of the tumor bulk [10]. Stemness factors Nanog and 
Sox2 are highly expressed in human embryonic stem (ES) cells with other stem cell marker, 
Lin28 and Oct4 together can reprogramed human somatic cells to pluripotencey [11]. The 
stemness factor, Nanog, has been shown to be upregulated in colorectal, hepatic, and brain 
cancer stem cells [12,13]. In brain tumors the CSCs were reported to express various stemness 
specific proteins such Sox2 and Oct3/4 [14]. Oct4/Sox2 heterodimers control the expression of 
Nanog, in which the heterodimers bind to the octamer/sox elements within the Nanog proximal 
promoter region and stimulate the Nanog transcription [15,16]. The upregulated expression of 
Nanog, Sox2 and Oct3/4 stemness genes have being involved in tumorigenicity, tumor 
transformation, tumor metastasis [17], and recurrence after chemoradiotherapy [18]. 
In the present study we determine whether ECT can modulate stemness inducing proteins 
(Oct4/3, Nanog, and Sox2) and measure the differential expression of these proteins in PDAC 
cells. These proteins may be the key players in the development of resistance, recurrence and 
disease progression after electrochemotherapy. 
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2. Methods: 
2.1. Cell culture 
The established human pancreatic cancer cell line PANC-1 was obtained from the American 
Type Culture Collection and the murine pancreatic cell line, Pan02 was obtained from the 
National Cancer Institute at Frederick. Both cell lines are well established models for the study 
of pancreatic cancer [29,30]. PANC-1 cells were maintained in Dulbeccos Modified Media 
supplemented with 20% (v/v) fetal calf serum, whilst Pan02 cells were maintained in RPMI 1640 
medium with 10% (v/v) fetal calf serum.  Both cell lines were supplemented with 1% 
penicillin/streptomycin, and were grown at 37°C, 5% CO2. 
2.2. Drug concentrations 
PANC-1: Bleomycin: 0.1μg/ml; 0.5μg/ml; 1μg/ml and 1.5μg/ml, Cisplatin: 0.1μg/ml; 0.2μg/ml; 
0.5μg/ml and 1.5μg/ml, Oxaliplatin: 1μg/ml, 2μg/ml, 3μg/ml and 4μg/ml 
 
Pan02: Bleomycin: 0.1μg/ml; 1μg/ml and 2.5μg/ml, Cisplatin: 0.5μg/ml; 1μg/ml; 2.5μg/ml and 
5μg/ml, Oxaliplatin: 0.2μg/ml; 0. 5μg/ml; 1μg/ml and 2μg/ml. 
2.3. Reversible electroporation and drug dose optimization 
Clonogenic assays were performed to determine the cells recovery after reversible 
electroporation with Bleomycin, Cisplatin or Oxaloplatin. Following harvesting, 2x106 cells 
were resuspended in 800μl of HEPES electroporation buffer (10 mM HEPES (Lonza), 250 mM 
sucrose and 1 mM MgCl2 in sterile water). Half of the cells suspension were electroporated in 
4mm cuvettes (VWR) in the presence of a range of drug concentrations (mentioned in section 
2.2) of three different chemotherapeutic drugs bleomycin, cisplatin and oxaliplatin separately 
and other half of the suspension (1x106/400 μl) was used as passively treated cells. Previously 
optimized parameters for reversible electroporation used were: 8 pulses of 99μs at a frequency of 
1Hz with 0.6kv/cm for PANC-1 cells or 1kv/cm for Pan02 cells using a BTX electroporator.   
Both actively (ECT) and passively treated cells with respective drugs along with untreated cells 
(control) were rested in the incubator at 37 oC for 30 minutes. After that, cells from all groups 
(actively and passively treated and untreated) were seeded in 6-well plates at densities as 
follows: 1500 cells per well for PANC-1 and 500 cells per well for Pan02, and allowed to grow 
for ten days. To visualize colonies, media was removed, cells were fixed in 96% ethanol for 10 
min and stained with Prodiff solution C (Braidwood laboratories 22009). Plates were scanned 
using the Odyssey IR imaging system (Li-Cor, Cambridge, United Kingdom) and colonies 
quantified.  Results are presented as integrated intensity ± SEM from at least three independent 
experiments. 
2.4. Cell viability through PI uptake 
Propidium iodide (PI) is a small fluorescent molecule that binds to DNA but cannot passively 
traverse into cells that possess an intact plasma membrane. PI uptake versus exclusion can thus 
be used to discriminate dead cells, in which plasma membranes become permeable regardless of 
the mechanism of death, from live cells with intact membranes.  After electroporation cells were 
seeded at a density of 32000 cell/ml and 16000 cell/ml (PANC-1) and 16000 cells/ml and 8000 
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cells/ml (Pan02) cells in a total of 2 ml in 6 well plates, for 24, 48hrs respectively. After the 
given time, cells were typsinised, washed in PBS and then propidium iodide added at 5ug/100ul. 
Samples were then run on the BD LSR II instrument. 
2.5. Evaluation of cell morphology 
Morphological features of cells treated by electroporation with bleomycin, cisplatin, and 
oxalipaltin were examined by light microscopy to confirm successful electroporation. Aliquots of 
untreated control and drug-treated were cytospun onto glass slides and stained using Pro-Diff 
(Braidwood Laboratories BAPROD1–fixed and stained with buffered eosin followed by methyl 
thionins). Cytospin images are representative of at least three independent experiments. 
2.6. Colony formation assay 
The ability of cells to recover from treatments and form colonies as a monolayer was assessed 
using a colony formation assay. Following treatment, either 250cells/ml of PANC-1 or 
100cells/ml of Pan02 cells were reseeded into a well of a six-well plate (in triplicate) each well 
contained of 4ml of nutrient medium. Cells were allowed to adhere and grow for one to two 
weeks. Visualization was carried out as per method in Section 2.3.  
2.7. Immunofluorescence 
Both cell lines were grown on cover slips for 48hours and then fixed with 4% paraformaldehyde 
(PFA) and permeabilized with 0.1% Triton X100. After blocking with 10% Fetal Bovine Serum 
+ 5% BSA + 1% fish gelatine in PBS 1x for 1hr, cells were washed 3 times with 1XPBS and 
then incubated for 2 hours at room temperature or overnight at 4oC with the primary antibody of 
interest diluted 1:250 in blocking solution [antibodies used: monoclonal Sox-2 Ab (E-4): sc-
365823, monoclonal Nanog (H-2): sc-374103 and the monoclonal Oct4 (C-10): sc-5279] (Santa 
Cruz Biotechnology, Heidelberg, Germany). and then washed 3 times with PBS for 5 minutes. 
The antigen-antibody complex was detected by incubation for 45 min with appropriate secondary 
antibody. The secondary antibodies Alexa Fluor 488 labeled with fluorescein (FITC) goat anti-
mouse IgG (Invitrogen Life Technologies, Carlsbad, CA) was used in a dilution of 1:500. The 
cells were then washed in PBS for 5 minutes and the nuclei were stained with a solution of 
DAPI. Cells were analyzed on a fluorescence microscope (Leica DM2000 LED, Leica 
microsystem, Germany) and images acquired using Leica application Suite 4.4.0 software. For 
each sample, repeated in triplicate, were performed three independent measurements and each 
measurement was normalized on background noise. 
2.8. Western blotting 
Following 48hours post treatment total cellular protein extracts were prepared by scraping the 
cells with modified RIPA buffer (50 mM Tris HCl (pH 7.4), 150 mM NaCl, 0.25% sodium 
deoxycholate, 1% Igepal, 1 mM EDTA, 1× Pefabloc, 1× protease inhibitor cocktail, 1 mM 
Na3VO4, 1 mM NaF). Equal concentrations (70ug) of each protein samples were separated on 
NuPAGE 4–12%, Bis-Tris gels (Invitrogen, NP0322) and electrophoretically transferred onto 
PVDF membranes. The membrane was incubated overnight at 4 degrees with the primary 
antibody of interest diluted 1:250 in TBS-1X-tween 0.1% solution [antibodies used: monoclonal 
Sox-2 Ab (E-4): sc-365823, monoclonal Nanog (H-2): sc-374103 and the monoclonal Oct4 (C-
10): sc-5279] (Santa Cruz Biotechnology, Heidelberg, Germany). Protein expression was 
visualized using the Odyssey IR imaging system (Li-Cor goat anti-mouse IgG 926 32211 IRDy 
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800). Level of expressional change was assessed with band intensity in comparison to untreated 
control.  
 
3. Results: 
3.1. Reversible electroporation and drug dose optimization 
Reversible electroporation is the application of an electrical field to increase the permeability of 
cell membranes to drugs that are otherwise impermeable. ECT potentiates the efficacy of drugs 
in tumors, whilst allowing for a lower therapeutic dose and subsequently reducing side effects.  It 
was observed that ECT significantly increased the efficacy of chemotherapies in both cell lines 
with optimized EP parameters mentioned in section 2.3. Figure 1a and 1b presents the recovery 
of PANC-1 and pan02 cell lines post treatment. The cell lines were exposed to a range of drug 
concentrations either by active (ECT) or passive treatment. The optimized dose for each drug 
was identified by the recovery of cells post treatment. Passive treatment of each dose was 
compared to ECT with the same dose. For all drugs ECT decreased the ability of cells to recover 
and proliferate. We selected those drug concentrations for all drugs as an optimized dose which 
has relatively less/no effect on cell recovery in passive treatment compared to dramatic reduction 
of cell recovery against ECT with same dose. The optimized drug concentration was identified as 
0.1μg/ml for Bleomycin in both cell lines, 0.2μg/ml of Cisplatin in PANC-1 and 3μg/ml in 
Pan02, and 3μg/ml of Oxaliplatin in PANC-1 and 0.2μg/ml in Pan02 as shown by blue dotted 
rectangles in Figure 1a and 1b. The recovery assay revealed the cells treated with ECT-
Bleomycin recovered less than the cells treated with ECT-Cisplatin and ECT-Oxaloplatin. This 
data suggests that bleomycin was a more potent chemotherapy drug as compared to cisplatin and 
oxaliplatin. 
3.2. Morphology and viability of pancreatic cells 
Treatment regimens of the pancreatic cells (PANC-1 and Pan02) included electroporation only, 
chemotherapy only, electrochemotherapy and untreated cells. 24hrs post treatment aliquots were 
removed for viability assessment. Morphological analysis revealed electroporation only induced 
transient changes including the presence of cytoplasmic vacuoles which confirmed that 
reversible electroporation had been taken place as indicated by green arrows in Figure 2b (ii) 
and Figure 3b (ii). Electroporation in the absence of any chemotherapy has changed the 
morphological characteristics of both cells types revealing the change in membrane potential and 
higher cell death as compared with untreated cells as shown in Figure 2 (a-i, b-ii) and Figure 
3(a-i, b-ii). Electroporation leads to increased uptake of chemotherapeutic agents during 
electrochemotherapy. Passive treatment showed the cytotoxic effect but the cell death increased 
approx. 2 times with the electrochemotherapy with each drug. Red arrows indicate dead cells 
(having no cytoplasmic contents) and blue arrows indicating dying cells (having unstable 
cytoplasmic content and disintegrated genomic contents) shown in Figure 2 and Figure 3. 
Morphological changes also revealed that the size of cells after electrochemotherapy were 
increased in comparison to passive treatment with bleomycin, cisplatin and oxaloplatin as shown 
in Figure 2b (iv, vi, vii) and Figure 3b (iv, vi, vii). Enlargement of cells and especially the 
disintegration of nuclear content was more obvious in case of bleomycin and oxaliplatin. 
Bleomycin is more potent as compared to cisplatin and oxaliplatin because it caused more cell 
7 
 
death as shown in Figures 2b (iv) and Figure 3b (iv).  This is also a strong indication of both the 
reversible mode of electroporation and the intracellular modification that with the passage of 
time cells modified themselves to efflux the drug but bleomycin molecule is as much larger as 
the cell after intracellular modifications were not able to get rid of bleomycin, which was the 
source of more cell death due to cytotoxicity which can be predicted from Figure 2 and Figure 
3. 
 
3.3. Recovery of pancreatic cells post treatment 
Colony formation ability of both cell lines were comparatively higher in electroporation only and 
when the cells were passively treated for 30 minutes with bleomycin, cisplatin and oxaloplatin 
which could be predicted from Figure 4 and Figure 5. Whist the pattern of cell recovery was 
dramatically decreased in both cell lines when they were electroporated in the presence of these 
drugs. The ability to recover in case of ECT-Bleomycin was very low in both PANC-1 and 
Pan02 in comparison to cisplatin and oxaloplatin, as shown in Figure 4 and Figure 5 
respectively. The recovery of cell in any case of drug treatment indicate there are some 
mechanisms/intracellular modification has been taken place in cancer cells which helped them to 
detoxify the effect of such a strong electrochemical treatment to reoccur again after the passage 
of time. One of possible modification might be the expressional changes in pluripotency factor 
which were the source to provide cancer cells the stem cell properties. 
3.4. Stemness factors expression in pancreatic cells post electrochemotherapy 
We have observed that both cell lines express Nanog, Sox2 and Oct4. As shown in Figure 6a 
and 7a, the expression of Oct3/4 decreased in drug treated cells as compared to untreated cells 
for both cell lines. Nanog expression was increased in the cells after electrochemotherapy in both 
cell lines shown in Figure 6c and 7c, whilst the expression of stem cell marker Sox2 remained 
constant in as shown in Figure 6b and 7b. To con firm the validity of expression pattern of stem 
cell marker as shown in immunofluorescence, western blot was performed. At the protein level, 
the expression patterns of these stem cell markers Nanog, Sox2 and Oct4 were parallel those of 
their respective immunofluorescence, as shown in the Figure 8.  The red dotted box in Figure 
8(i, a) indicates the higher band intensity for enhanced expression of Nanog after 
electrochemtherapy in both cell lines as compared to untreated control and passively treated 
samples, and similarly the blue dotted box in Figure 8(ii, b) showed the decreased in band 
intensity for Oct3/4 in treated cell samples which indicate downregulation of Oct3/4 in drug 
treated samples in comparison to untreated control.  
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4. Discussion/Conclusion: 
For many chemotherapeutic agents the response rate is low because the chemotherapy cannot 
readily reach their intracellular site of action. For such drugs, the cell membrane is often a 
significant barrier that reduces effectiveness by restricting intracellular access. Electroporation 
uses short intense electric pulses to increase the plasma membrane permeability which allows the 
introduction of non- or poorly permeant molecules into the cells [5-6]. Electrochemotherapy 
(ECT) is the combination of chemotherapeutic drug with these optimized pulses which augment 
the drug delivery inside the cell and therefore increasing the efficacy of chemotherapy. 
Electrochemotherapy has increased the effectiveness of non-permeant chemotherapeutic drugs 
such as bleomycin by several fold. Overall the effectiveness of electrochemotherapy is 
approximately 80% and is considered an effective and safe local ablative treatment [19].  Studies 
have indicated other mechanisms including vascular disrupting effect and immune response are 
also involved during the application of electrochemotherapy which help to make this treatment 
application very attractive in the clinic [7,20,28]. Electrochemotherapy has been established as 
an effective treatment of skin tumors of different histology and has been successful in the 
treatment of internal tumors such as liver and colorectal [21].  
In the present study we examined the viability and recovery of pancreatic cancer cells post 
electrochemotherapy with bleomycin, cisplatin and oxaliplatin. Electrochemotherapy with 
bleomycin exhibited a higher cell death rate over cisplatin and oxaliplatin. Morphological 
changes revealed that the size of cells after electrochemotherapy were increased as compared 
with passive treatment with bleomycin, cisplatin and oxaliplatin. Enlargement of cells and 
especially the disintegration of nuclear content was more obvious in case of bleomycin 
indicating its potent cytotoxicity and therefore demonstrating ECT as a very effective treatment. 
Recovery of the pancreatic cancer cells were also measured which showed that the cells 
recovered to some degree after electrochemotherapy. The ability to recover in case of 
electrochemotherapy with bleomycin was low in both cell lines in comparison to cisplatin and 
oxaliplatin. This recovery represents a major challenge to this treatment and if unresolved may 
lead to recurrence.  
The recovery of cells in any drug treatment indicates there are some mechanisms or intracellular 
modifications that has been taken place in the treated cells which helped them to detoxify the 
effect of drugs. One possible modification might be the expression changes of stemness genes 
that has the potential to generate recurrence in pancreatic cancer cells after electrochemotherapy 
and such expressional changes in these genes give them the properties of cancer stem cells CSC, 
a small and distinct population of cancer cells that mediates tumoregenesis, metastasis and 
resistance to standard treatments. Evidence for the existence of cancer stem cells was first 
reported in human acute myeloid leukemia in the 1990s and subsequently were identified in 
various solid tumors including breast cancer, brain tumor, prostate cancer, pancreatic cancer, 
ovarian cancer [22]. The embryonic stemness inducing factor, Nanog sex determine region Y-
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box 2 (Sox2), octamer-binding transcription factor 4, Oct4, for instance, were shown to be highly 
express in the CSCs in hepatic, colorectal, and brain CSCs [12,13,14]. The Oct4/Sox2 
heterodimers, regulate the expression of Nanog by binding to the octamer/sox elements within 
the Nanog proximal promoter region and induces Nanog transcription [15,16]. The critical role 
of these factors in reprogramming processes makes them essential not only for embryonic 
development but also tumorigenesis. Recent data showed that the overexpression of Nanog, Sox2 
and Oct3/4 together or separately, led to tumor transformation, tumorigenicity, tumor metastasis, 
and even distant recurrence after chemoradiotherapy [23]. Data from our study indicate that 
electrochemotherapy has an effect on the stemness-associated markers.  Many anti-cancer 
therapies are evaluated based on their ability to shrink tumors [24], but if the therapies are not 
targeting the cancer stem cells, then the tumor will most likely relapse. The cancer stem cell 
theory suggests that a few cancer cells can act as stem cells and reproduce themselves causing 
recurrence [25].  
Our study revealed that the expression of master stemness inducing factor Nanog was increased 
in the cells electroporated in the presence of drugs in both human and murine cell lines (Figure 
6c and 7c), whilst the expression of Oct3/4 decreases with the treatment in both PANC-1 and 
Pan02 cell lines. Interestingly the expression of stem cell marker Sox2 remain relatively constant 
in both cell lines as shown in Figure 6b and 7b. As one approach to better understanding the 
functional significance of Sox2, we examined the expression in both the PANC-1 and Pan02 
lines by immunofluorescence indicated that it mainly localized to the cell nucleus (Figure 6a 
and 7b) that indicate its role in the transcription of master stemness marker the Nanog [26, 27]. 
Whilst the decreased in expression of Oct4 correlated with the expression of Akt which promote 
the self-renewal and cell survival of cancer cells [26]. To confirm the validity of expression 
pattern of stem cell marker as shown in immunofluorescence, western blot was performed. At the 
protein level, the expression patterns of these stem cell markers Nanog, Sox2 and Oct4 were 
parallel to those of their respective immunofluorescence, as shown in the Figure 8.  
In conclusion, we present data demonstrating changes in stemness factors after 
electrochmeotherapy. The altered expression of the stemness markers have the potential to allow 
for recurance post treatment. With the advancement of electrochemotherapy as a cancer 
treatment for deep seated tumors including pancreatic cancer our results warrant further 
investigation to improve upon the treatment.  
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Figure legends: 
Figure 1a. Chemotherapy dose optimization for Electrochemotherapy in PANC-1 cells. 
ECT dramatically reduced the capability of cancer cells to recover and proliferate relative to 
chemotherapy alone. Blue dotted rectangles indicate the optimized drug dose of bleomycin, 
cisplatin and oxaloplatin. Each well shown is a representative image of at least three independent 
experiments. Data also presented in line graphs as mean IKK ± SD M of three independent 
experiments.  
Figure 1b. Chemotherapy dose optimization for Electrochemotherapy in Pan02 cells. ECT 
dramatically reduced the capability of cancer cells to recover and proliferate relative to 
chemotherapy alone. Blue dotted rectangles indicate the optimized drug dose of bleomycin, 
cisplatin and oxaloplatin. Each well shown is a representative image of at least three independent 
experiments. Data also presented in line graphs as mean IKK ± SD M of three independent 
experiments. 
Figure 2: Morphological changes viability after electroporation in PANC-1. Following 
24hours post treatment viability was analyzed through flow cytometry and morphology by 
cytospinning. Electroporation leads to transient morphological changes in pancreatic cancer cells 
including the presence of cytoplasmic vacuoles and leads to increased uptake of drugs with 
correspondence to their viability. Red arrows indicate the dead cells and blue arrows indicating 
the dying cells. PI uptake indicates the percentage of dead cells which is shown in P2 population. 
Figure 3: Morphological changes and viability after electroporation in Pan02. Following 
24hours post treatment viability was analyzed through flow cytometry and morphology by 
cytospinning. Electroporation leads to transient morphological changes in pancreatic cancer cells 
including the presence of cytoplasmic vacuoles and leads to increased uptake of drugs with 
13 
 
correspondence to their viability. Red arrows indicate the dead cells and blue arrows indicating 
the dying cells. PI uptake indicates the percentage of dead cells which is shown in P2 population. 
Figure 4: PANC-1 cell recovery in response to drug therapy alone vs. combination therapy 
consisting of drug of interest and simultaneous electroporation. Cells treated with ECT- 
bleomycin recovered less than the cells treated with ECT-Cisplatin and ECT-Oxaloplatin. Each 
well shown is a representative image of at least nine similar wells (three independent 
experiments). Data also presented in bar graphs as mean IKK ± SD M of three independent 
experiments. 
 
Figure 5: Pan02 cell recovery in response to drug therapy alone vs. combination therapy 
consisting of drug of interest and simultaneous electroporation. Cells treated with ECT - 
bleomycin recovered less than the cells treated with ECT-Cisplatin and ECT-Oxaloplatin. Each 
well shown is a representative image of at least nine similar wells (three independent 
experiments). Data also presented in bar graphs as mean IKK ± SD M of three independent 
experiments. 
Figure 6: Differential expression of stemness factors Oct4/3, Nanog and Sox2 after 
Electrochemotherapy. Following 48 hours post treatment immunofluorescence of PANC-1 cells 
grown on cover slips was done by using anti-Oct3/4 (green), anti-Sox2 (green) and anti-Nanog 
(green) antibodies. DAPI staining (blue) indicates cell nuclei. The blue arrowhead indicates that 
the expression of Oct3/4 in untreated cells is comparatively higher compared with treated cells. 
The white arrowhead indicates a cell expressing higher quantity of Nanog stem cell marker. 
Figure 7: Differential expression of stemness factors Oct4/3, Nanog and Sox2 after 
Electrochemotherapy. Following 48hours post treatment immunofluorescence of Pan02 cells 
grown on cover slips was done by using anti-Oct3/4 (green), anti-Sox2 (green) and anti-Nanog 
(green) antibodies. DAPI staining (blue) indicates cell nuclei. The blue arrowhead indicates that 
the expression of Oct3/4 in untreated cells is comparatively higher compared with treated cells. 
The white arrowhead indicates a cell expressing higher quantity of Nanog stem cell marker. 
Figure 8: Expressional changes of stemness genes Oct4/3, Nanog and Sox2 post 
Electrochemotherapy. Total proteins were extracted (after 48hours growth) from human 
pancreatic cells line. Proteins were resolved by SDS polyacrylamide gel electrophoresis and 
analyzed by western blot. The antibodies used in the western blot analysis are indicated on the 
left. The relative change in expression of Nanog, Oct3/4 and Sox2 are graphically presented in 
(a), (b) and (c) respectively. Red box indicates enhanced expression of Nong after ECT, whilst 
blue box indicates relative decrease in expression after treatment. β -Actin was used as a loading 
control. 
 
 
